Executive function changes before memory in preclinical Alzheimer's pathology: A prospective, cross-sectional, case control study

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Harrington, Michael G ^a   Chiang, Jiarong ^a   Pogoda, Janice M ^b   Gomez, Megan ^c   Thomas, Kris ^c   Marion, Sarah DeBoard ^c   Miller, Karen J ^d   Siddarth, Prabha ^d   Yi, Xinyao ^e   Zhou, Feimeng ^e   Lee, Sherri ^a   Arakaki, Xianghong ^a   Cowan, Robert P ^f   Tran, Thao ^a   Charleswell, Cherise ^a   Ross, Brian D ^a   Fonteh, Alfred N ^a  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c FULLER THEOLOGICAL SEMINARY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CALIFORNIA STATE UNIVERSITY   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; EXECUTIVE FUNCTION; FEMALE; GENOTYPE; HUMANS; MALE; MODELS, STATISTICAL; PROSPECTIVE STUDIES;

EID: 84894114500     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079378     Document Type: Article

References (79)

1. Sperling RA, Karlawish J, Johnson KA (2013) Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol 9: 54-58.
2. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, et al. (2001) Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 47: 1776-1781. (Pubitemid 32881189)
3. Wang L, Fagan AM, Shah AR, Beg MF, Csernansky JG, et al. (2012) Cerebrospinal fluid proteins predict longitudinal hippocampal degeneration in early-stage dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 26: 314-321.
4. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al. (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280-292.
5. Jack CR Jr., Knopman DS, Weigand SD, Wiste HJ, Vemuri P, et al. (2012) An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71: 765-775.
6. Irwin DJ, Trojanowski JQ, Grossman M (2013) Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. Front Aging Neurosci 5: 6.
7. Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, et al. (2011) Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 68: 1137-1144.
8. Mograbi DC, Ferri CP, Sosa AL, Stewart R, Laks J, et al. (2012) Unawareness of memory impairment in dementia: a population-based study. Int Psychogeriatr 24: 931-939.
9. Jessen F, Wolfsgruber S, Wiese B, Bickel H, Mosch E, et al. (2013) AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimers Dement.
10. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256: 183-194.
11. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., et al. (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263-269.
12. Williams MM, Storandt M, Roe CM, Morris JC (2013) Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores. Alzheimers Dement 9: S39-44.
13. Pillai JA, Cummings JL (2013) Clinical trials in predementia stages of Alzheimer disease. Med Clin North Am 97: 439-457.
14. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, et al. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367: 795-804.
15. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, et al. (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64: 343-349. (Pubitemid 46425688)
16. Holtzman DM, Mandelkow E, Selkoe DJ (2012) Alzheimer disease in 2020. Cold Spring Harb Perspect Med 2.
17. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148: 1204-1222.
18. Selkoe D, Mandelkow E, Holtzman D (2012) Deciphering Alzheimer disease. Cold Spring Harb Perspect Med 2: a011460.
19. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
20. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319. (Pubitemid 38269583)
21. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, et al. (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355: 2652-2663. (Pubitemid 44969124)
22. Small GW, Siddarth P, Kepe V, Ercoli LM, Burggren AC, et al. (2012) Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol 69: 215-222.
23. Ono M, Saji H (2012) Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: novel PET/SPECT imaging probes for diagnosis of Alzheimer's disease. J Pharmacol Sci 118: 338-344.
24. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, et al. (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34: 457-468.
25. Clark LR, Schiehser DM, Weissberger GH, Salmon DP, Delis DC, et al. (2012) Specific measures of executive function predict cognitive decline in older adults. J Int Neuropsychol Soc 18: 118-127.
26. Johnson DK, Storandt M, Morris JC, Galvin JE (2009) Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol 66: 1254-1259.
27. Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, et al. (2007) The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. Alzheimer Dis Assoc Disord 21: 249-258. (Pubitemid 47367978)
28. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, et al. (2013) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 12: 822-838.
29. Godbolt AK, Waldman AD, MacManus DG, Schott JM, Frost C, et al. (2006) MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 66: 718-722. (Pubitemid 43739827)
30. Kantarci K, Weigand SD, Przybelski SA, Preboske GM, Pankratz VS, et al. (2013) MRI and MRS predictors of mild cognitive impairment in a population-based sample. Neurology 81: 126-133.
31. Kantarci K, Weigand SD, Przybelski SA, Shiung MM, Whitwell JL, et al. (2009) Risk of dementia in MCI: combined effect of cerebrovascular disease, volumetric MRI, and 1H MRS. Neurology 72: 1519-1525.
32. Pfeffer RI, Kurosaki TT, Harrah CH Jr., Chance JM, Filos S (1982) Measurement of functional activities in older adults in the community. J Gerontol 37: 323-329. (Pubitemid 12117513)
33. Crum RM, Anthony JC, Bassett SS, Folstein MF (1993) Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 269: 2386-2391. (Pubitemid 23129378)
34. Freitas S, Simoes MR, Alves L, Santana I (2011) Montreal Cognitive Assessment: Validation Study for Mild Cognitive Impairment and Alzheimer Disease. Alzheimer Dis Assoc Disord.
35. Yesavage JA (1988) Geriatric Depression Scale. Psychopharmacol Bull 24: 709-711.
36. Berg L, Miller JP, Storandt M, Duchek J, Morris JC, et al. (1988) Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment. Ann Neurol 23: 477-484.
37. McFarlane J, Welch J, Rodgers J (2006) Severity of Alzheimer's disease and effect on premorbid measures of intelligence. Br J Clin Psychol 45: 453-463. (Pubitemid 46017357)
38. Wechsler D (1997) WAIS-III administration and scoring manual. San Antonio, TX: The Psychological Corporation.
39. Pilgrim BM, Meyers JE, Bayless J, Whetstone MM (1999) Validity of the Ward seven-subtest WAIS-III short form in a neuropsychological population. Appl Neuropsychol 6: 243-246. (Pubitemid 30030306)
40. Wechsler D (1997) WAIS-III-WMS-III technical manual. San Antonio, TX.
41. Delis JHK, Kaplan E, Ober BA (2000). California Verbal Learning Test-Second Edition. San Antonio, TX: Psychological Corporation.
42. Gallagher C, Burke T (2007) Age, gender and IQ effects on the Rey-Osterrieth Complex Figure Test. Br J Clin Psychol 46: 35-45. (Pubitemid 46332276)
43. Steinberg BA, Bieliauskas LA, Smith GE, Langellotti C, Ivnik RJ (2005) Mayo's Older Americans Normative Studies: Age- and IQ-Adjusted Norms for the Boston Naming Test, the MAE Token Test, and the Judgment of Line Orientation Test. Clin Neuropsychol 19: 280-328. (Pubitemid 41153286)
44. Loonstra AS, Tarlow AR, Sellers AH (2001) COWAT metanorms across age, education, and gender. Appl Neuropsychol 8: 161-166. (Pubitemid 32976968)
45. Tombaugh TN, Kozak J, Rees L (1999) Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol 14: 167-177. (Pubitemid 29108542)
46. Tombaugh TN (2004) Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol 19: 203-214.
47. Seo EH, Lee DY, Choo IH, Kim SG, Kim KW, et al. (2008) Normative study of the Stroop Color and Word Test in an educationally diverse elderly population. Int J Geriatr Psychiatry 23: 1020-1027.
48. Delis DC, Kramer JH, Kaplan E, Holdnack J (2004) Reliability and validity of the Delis-Kaplan Executive Function System: an update. J Int Neuropsychol Soc 10: 301-303. (Pubitemid 38418188)
49. Benedict RH (2005) Effects of using same- versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis. J Int Neuropsychol Soc 11: 727-736.
50. Gale SD, Baxter L, Connor DJ, Herring A, Comer J (2007) Sex differences on the Rey Auditory Verbal Learning Test and the Brief Visuospatial Memory Test-Revised in the elderly: normative data in 172 participants. J Clin Exp Neuropsychol 29: 561-567. (Pubitemid 46918927)
51. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944. (Pubitemid 14076461)
52. Seshadri S, Beiser A, Au R, Wolf PA, Evans DA, et al. (2011) Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 2. Alzheimers Dement 7: 35-52.
53. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, et al. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863-1872. (Pubitemid 43970103)
54. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, et al. (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134: 2456-2477.
55. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, et al. (1992) Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 42: 473-480.
56. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, et al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43: 1467-1472.
57. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, et al. (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 1: 371-380.
58. Mielke MM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, et al. (2012) Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology 79: 1570-1577.
59. Saxton J, Lopez OL, Ratcliff G, Dulberg C, Fried LP, et al. (2004) Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology 63: 2341-2347. (Pubitemid 40024347)
60. Weintraub S, Wicklund AH, Salmon DP (2012) The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med 2: a006171.
61. Hedden T, Oh H, Younger AP, Patel TA (2013) Meta-analysis of amyloidcognition relations in cognitively normal older adults. Neurology 80: 1341-1348.
62. Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, et al. (2013) Criteria for mild cognitive impairment due to alzheimer's disease in the community. Ann Neurol.
63. Schott JM, Bartlett JW, Fox NC, Barnes J (2010) Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann Neurol 68: 825-834.
64. Duchek JM, Balota DA, Tse CS, Holtzman DM, Fagan AM, et al. (2009) The utility of intraindividual variability in selective attention tasks as an early marker for Alzheimer's disease. Neuropsychology 23: 746-758.
65. Balota DA, Tse CS, Hutchison KA, Spieler DH, Duchek JM, et al. (2010) Predicting conversion to dementia of the Alzheimer's type in a healthy control sample: the power of errors in Stroop color naming. Psychol Aging 25: 208-218.
66. Hutchison KA, Balota DA, Duchek JM (2010) The utility of Stroop task switching as a marker for early-stage Alzheimer's disease. Psychol Aging 25: 545-559.
67. Nee DE, Wager TD, Jonides J (2007) Interference resolution: insights from a meta-analysis of neuroimaging tasks. Cogn Affect Behav Neurosci 7: 1-17. (Pubitemid 46871522)
68. Kramer JH, Reed BR, Mungas D, Weiner MW, Chui HC (2002) Executive dysfunction in subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry 72: 217-220.
69. Chao LL, Decarli C, Kriger S, Truran D, Zhang Y, et al. (2013) Associations between white matter hyperintensities and beta amyloid on integrity of projection, association, and limbic fiber tracts measured with diffusion tensor MRI. PLoS One 8: e65175.
70. Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, et al. (1997) In vivo magnetic resonance spectroscopy of human brain: the biophysical basis of dementia. Biophys Chem 68: 161-172. (Pubitemid 28064663)
71. Parra MA, Abrahams S, Logie RH, Mendez LG, Lopera F, et al. (2010) Visual short-term memory binding deficits in familial Alzheimer's disease. Brain 133: 2702-2713.
72. Dewar M, Pesallaccia M, Cowan N, Provinciali L, Della Sala S (2012) Insights into spared memory capacity in amnestic MCI and Alzheimer's Disease via minimal interference. Brain Cogn 78: 189-199.
73. Braak H, Braak E, Bohl J (1993) Staging of Alzheimer-related cortical destruction. Eur Neurol 33: 403-408. (Pubitemid 23358066)
74. Gomez-Isla T, Price JL, McKeel DW, Jr., Morris JC, Growdon JH, et al. (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16: 4491-4500. (Pubitemid 26243044)
75. Vlassenko AG, Mintun MA, Xiong C, Sheline YI, Goate AM, et al. (2011) Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol 70: 857-861.
76. Sambataro F, Safrin M, Lemaitre HS, Steele SU, Das SB, et al. (2012) Normal aging modulates prefrontoparietal networks underlying multiple memory processes. Eur J Neurosci 36: 3559-3567.
77. Galvin JE, Fagan AM, Holtzman DM, Mintun MA, Morris JC (2010) Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain 133: 3290-3300.
78. Byrne H, Smith N, Batt E (1995) Dementia assessment: to do or not to do? Aust J Adv Nurs 13: 18-21.
79. Endo K, Matsukawa K, Liang N, Nakatsuka C, Tsuchimochi H, et al. (2013) Dynamic exercise improves cognitive function in association with increased prefrontal oxygenation. J Physiol Sci.